In 2026, we will mark an important milestone in public health: 20 years since the human papillomavirus (HPV) vaccine was approved by the FDA. Over the past two decades, this vaccine has quietly transformed the future of cancer prevention—especially when it comes to cervical cancer. What began as a promising scientific breakthrough has become one of the most effective tools we have to protect long-term health. This blog explores what HPV is, how the HPV vaccine works, why cervical health matters, and what two decades of data tell us about the vaccine’s real-world impact. Most importantly, it’s a moment to reflect on progress made—and on the work still ahead.
What Is HPV?
Human papillomavirus (HPV) is one of the most common viruses in the world. In fact, nearly all sexually active people will be exposed to HPV at some point in their lives, often without ever knowing it. HPV spreads through intimate skin-to-skin contact and does not require penetrative sex to be transmitted. There are more than 100 types of HPV. Many are considered low-risk and may cause no symptoms or only mild health issues, such as genital warts. Others are classified as high-risk HPV strains, which can persist in the body and lead to cancer over time. Persistent infection with high-risk HPV—especially types 16 and 18—is the primary cause of cervical cancer. While most HPV infections resolve on their own, those that don’t can cause cellular changes that develop slowly over many years. This long progression makes prevention especially powerful.
What Is the HPV Vaccine?
The HPV vaccine works by training the immune system to recognize and fight high-risk HPV types before exposure occurs. It does not treat existing infections, which is why timing matters. The vaccine protects against the HPV strains most commonly linked to cancer, including those responsible for most cervical cancer cases. It also helps prevent other HPV-related cancers, such as cancers of the anus, throat, penis, vulva, and vagina, though cervical cancer prevention remains a central focus.
When Is the Vaccine Given?
- Ages 9–14: Two doses
- Ages 15 and older (or immunocompromised individuals): May require three doses
By vaccinating early, we protect adolescents long before they are at risk, creating a foundation for lifelong cancer prevention.
Why Cervical Health Matters
The cervix plays an essential role in reproductive and overall health for women and people with a cervix. Cervical cancer develops gradually, often without noticeable symptoms in its early stages, making prevention and screening especially important. The HPV vaccine helps stop cervical cancer before it begins, but it works best when paired with routine cervical cancer screening later in life, such as Pap tests and HPV testing. Together, vaccination and screening form a powerful prevention strategy. Preventing cancer isn’t just about avoiding illness, it’s about preserving long-term health, well-being, and quality of life. Vaccinating adolescents today protects them well into adulthood, long after the shots themselves are forgotten.
The HPV Vaccine is for Everyone
Although the focus of this blog is on National Cervical Health Awareness Month, it’s important to recognize that HPV vaccination is recommended for males as well. Males can both contract and transmit the virus. According to the Cleveland Clinic, the HPV vaccine is recommended for people of all sexes and can protect against cancers of the cervix, penis, anus, and throat.(1)
While we continue to spread awareness for cervical health this January, it is important to remember that the HPV vaccine is for everyone, including males.
Health Equity and Cervical Cancer Prevention
Despite being largely preventable, cervical cancer does not affect all communities equally. Underserved populations experience higher rates of cervical cancer and lower screening rates. Transgender and gender-diverse individuals with a cervix face additional barriers, including gender dysphoria, stigma in healthcare settings, and lack of provider awareness. These challenges can lead to delayed screening or missed preventive care altogether. Expanding HPV vaccination and improving access to inclusive, affirming healthcare are essential steps toward closing these gaps and making cancer prevention truly equitable.
20 Years of the HPV Vaccine: What the Data Show
Since the HPV vaccine was introduced in 2006, research from the U.S. and around the world has shown substantial declines in HPV infections, precancerous cervical lesions, and cervical cancer diagnoses, particularly among younger populations who were vaccinated early. Studies consistently show that:
- Over 130 million doses of the HPV vaccine have been administered since 2006 in the US.(2)
- HPV infections from vaccine-covered strains have dropped dramatically among adolescents and young adults.(3)
- Precancerous cervical changes have declined in vaccinated populations.(4)
- Individuals diagnosed with cervical cancer are significantly less likely to have been vaccinated.(5)
These outcomes demonstrate real-world effectiveness. Two decades in, the evidence is clear: the HPV vaccine works.
Looking Ahead: A Call to Action
The HPV vaccine stands as one of the most powerful cancer-prevention tools ever developed. It has already saved lives, and its full impact will continue to unfold in the decades ahead. If you or your child have not yet received the HPV vaccine, it’s not too late. And if you’ve started the series but haven’t completed it, now is a great time to catch up. Prioritizing cervical health means prioritizing prevention, access, and informed decision-making. As we celebrate 20 years of progress, let’s also recommit to the goal that inspired this vaccine in the first place: a future where cervical cancer is rare and preventable for everyone.
1. Cleveland Clinic. (2023). HPV vaccine: What you need to know. https://my.clevelandclinic.org/health/treatments/21613-hpv-vaccine
2. Gavi, the Vaccine Alliance. (2025, November 17). The HPV vaccine is erasing cancer — here’s the proof. Gavi. https://www.gavi.org/vaccineswork/hpv-vaccine-erasing-cancer-heres-proof?utm
3. Yale School of Public Health. Cervical Precancers Drop Dramatically. (2025). Highlights substantial declines in precancerous cervical lesions among young women since introduction of the HPV vaccine. Retrieved from https://ysph.yale.edu/news-article/cervical-precancers-drop-dramatically/
4. Gargano JW, Stefanos R, Dahl RM, et al. Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022. Morbidity and Mortality Weekly Report (MMWR). 2025;74(6):96–101.
5. University of Manchester. New research confirms HPV vaccination prevents cervical cancer (2025). Highlights that vaccination before age 16 is associated with an ~80% lower risk of cervical cancer and reduced precancerous lesions.
